Journal article
Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate Cancer
Abstract
BACKGROUND: Whether stereotactic body radiotherapy (SBRT) is noninferior to conventionally or moderately hypofractionated regimens with respect to biochemical or clinical failure in patients with localized prostate cancer is unclear.
METHODS: We conducted a phase 3, international, open-label, randomized, controlled trial. Men with stage T1 or T2 prostate cancer, a Gleason score of 3+4 or less, and a prostate-specific antigen (PSA) level of no …
Authors
van As N; Griffin C; Tree A; Patel J; Ostler P; van der Voet H; Loblaw A; Chu W; Ford D; Tolan S
Journal
The New England Journal of Medicine, Vol. 391, No. 15, pp. 1413–1425
Publisher
Massachusetts Medical Society
Publication Date
October 17, 2024
DOI
10.1056/nejmoa2403365
ISSN
0028-4793